Gilead to Acquire Tubulis in $3.15B Deal with Up to $1.85B in Milestones

Foster City, CA and Munich, Germany, April 7, 2026 (Business Wire) -- Gilead Sciences has announced plans to acquire Tubulis to enhance its cancer treatment portfolio. The deal includes $3.15 billion in upfront cash, along with potential milestone payments that could bring the total value significantly higher. The acquisition adds advanced antibody-drug conjugate (ADC) candidates and platform technologies aimed at strengthening Gilead’s next-generation oncology pipeline.

Read full article here.